Regulatory Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data BioSpaceThe FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.RegulatoryMetabolic & GLP-1Read full story pharminent April 15, 2026 BioSpace The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In SilicoNext: Amazon launches its AI drug discovery platform Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026